Matricelf Ltd. MTLF
TASE · Israel · Health Technology
ILA 255.00-2.80 (-1.09%)
Market closed· · ILA · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · ILA · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
CHARLOTTE, N.C., September 10, 2026--Zero Networks, the leading provider of Zero Trust security solutions, today announced the appointment of Yossi Dagan as Chief Financial Officer (CFO), further strengthening its executive leadership team as the company scales its global business and continues to see growing enterprise demand for automated microsegmentation.
Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing a personalized, autologous neural tissue transplant for the treatment of spinal cord injury, today announced that it has received written feedback from the U.S. Food and Drug Administration, FDA, Center for Biologics Evaluation and Research, CBER, regarding the proposed design of the Company's first in human clinical trial of NewRal.
Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized, autologous engineered neural tissue for the treatment of spinal cord injury (SCI), today announced that it has received approval from the Helsinki Committee (Institutional Review Board) and the Director of Loewenstein Rehabilitation Medical Center, Israel's leading rehabilitation hospital and one of the country's premier referral centers for spinal cord injury, to begin collecting blood samples from eligible pa
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.